ストックスクリーナーアプリを入手
29.34
3.31%
0.94
アフターアワーズ：
29.34
前日終値:
$28.40
開ける：
$28.09
24時間の取引高:
1.48M
Relative Volume:
2.52
時価総額：
$2.05B
収益：
-
当期純損益:
$-237.22M
株価収益率:
-11.46
EPS:
-2.56
ネットキャッシュフロー:
$-212.64M
1週間 パフォーマンス:
+1.56%
1か月 パフォーマンス:
-4.23%
6か月 パフォーマンス:
+34.71%
1年 パフォーマンス:
+36.09%
1日の値動き範囲:
$28.09
$29.77
1週間の範囲:
$27.35
$31.41
52週間の値動き範囲:
$15.32
$37.00
Akero Therapeutics Inc Stock (AKRO) Company Profile
名前
Akero Therapeutics Inc
セクター
電話
650-487-6488
住所
601 GATEWAY BOULEVARD, SUITE 350, SOUTH SAN FRANCISCO, CA
AKRO を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
AKRO
Akero Therapeutics Inc
|
29.34 | 2.05B | 0 | -237.22M | -212.64M | -3.78 |
|
VRTX
Vertex Pharmaceuticals Inc
|
397.27 | 102.31B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
701.85 | 77.13B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
623.82 | 37.30B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
245.44 | 31.66B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
113.08 | 27.11B | 3.30B | -501.07M | 1.03B | -2.1146 |
Akero Therapeutics Inc Stock (AKRO) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2024-11-18 | 開始されました | Citigroup | Buy |
| 2024-04-22 | 再開されました | BofA Securities | Neutral |
| 2023-09-19 | 開始されました | Cantor Fitzgerald | Overweight |
| 2023-08-28 | 開始されました | UBS | Buy |
| 2023-01-27 | アップグレード | Morgan Stanley | Equal-Weight → Overweight |
| 2022-09-14 | アップグレード | Evercore ISI | In-line → Outperform |
| 2021-10-19 | ダウングレード | Morgan Stanley | Overweight → Equal-Weight |
| 2021-09-10 | 開始されました | BofA Securities | Buy |
| 2021-02-26 | 開始されました | Guggenheim | Buy |
| 2020-09-10 | 開始されました | Morgan Stanley | Overweight |
| 2020-07-20 | 繰り返されました | H.C. Wainwright | Buy |
| 2020-07-07 | 開始されました | Chardan Capital Markets | Buy |
| 2020-07-01 | 繰り返されました | H.C. Wainwright | Buy |
| 2020-03-02 | 開始されました | H.C. Wainwright | Buy |
| 2020-02-10 | 開始されました | Canaccord Genuity | Buy |
| 2019-07-15 | 開始されました | Evercore ISI | Outperform |
| 2019-07-15 | 開始されました | JP Morgan | Overweight |
| 2019-07-15 | 開始されました | Jefferies | Buy |
| 2019-07-15 | 開始されました | ROTH Capital | Buy |
すべてを表示
Akero Therapeutics Inc (AKRO) 最新ニュース
Akero Therapeutics' senior VP Patrick Lamy sells $29,130 in stock By Investing.com - Investing.com Australia
Akero Therapeutics' senior VP Patrick Lamy sells $29,130 in stock - Investing.com India
Insider Selling: Akero Therapeutics, Inc. (NASDAQ:AKRO) VP Sells 1,000 Shares of Stock - MarketBeat
Catriona Yale Sells 9,074 Shares of Akero Therapeutics, Inc. (NASDAQ:AKRO) Stock - MarketBeat
Akero Therapeutics chief scientific officer sells $118,172 in stock By Investing.com - Investing.com South Africa
Akero Therapeutics executive sells $264k in stock By Investing.com - Investing.com Canada
Akero Therapeutics chief scientific officer sells $118,172 in stock - Investing.com
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Akero Therapeutics, Inc. (AKRO) And Encourages Stockholders to Reach Out - AccessWire
Akero Therapeutics (NASDAQ:AKRO) Trading Down 4.1%What's Next? - MarketBeat
State Street Corp Has $71.81 Million Stock Holdings in Akero Therapeutics, Inc. (NASDAQ:AKRO) - MarketBeat
Fmr LLC Purchases 26,691 Shares of Akero Therapeutics, Inc. (NASDAQ:AKRO) - MarketBeat
Akero Therapeutics (NASDAQ:AKRO) Shares Up 3.5%Here's What Happened - MarketBeat
AKERO THERAPEUTICS INVESTIGATION INITIATED BY FORMER LOUISIANA ATTORNEY GENERAL: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Akero Therapeutics, Inc.AKRO - The Eastern Progress Online
Bronstein, Gewirtz & Grossman, LLC Is Investigating Akero Therapeutics, Inc. (AKRO) And Encourages Stockholders to Connect - AccessWire
Akero Therapeutics, Inc. (NASDAQ:AKRO) Short Interest Down 9.1% in November - MarketBeat
Akero Therapeutics' chief development officer sells $86,519 in stock By Investing.com - Investing.com South Africa
Akero Therapeutics chief scientific officer sells $148,933 in shares By Investing.com - Investing.com Canada
Akero Therapeutics COO sells shares worth $77,067 - Investing.com India
Akero Therapeutics COO sells shares worth $77,067 By Investing.com - Investing.com South Africa
Akero Therapeutics executive sells $28,480 in common stock By Investing.com - Investing.com South Africa
Akero Therapeutics CFO sells $86,735 in stock By Investing.com - Investing.com Canada
Akero Therapeutics CFO sells $86,735 in stock - Investing.com
Akero Therapeutics' chief development officer sells $86,519 in stock - Investing.com
(AKRO) Technical Data - Stock Traders Daily
Akero Therapeutics, Inc. (AKRO) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation - AccessWire
Wellington Management Group LLP Purchases 2,782,029 Shares of Akero Therapeutics, Inc. (NASDAQ:AKRO) - MarketBeat
Charles Schwab Investment Management Inc. Sells 22,269 Shares of Akero Therapeutics, Inc. (NASDAQ:AKRO) - MarketBeat
RTW Investments LP Purchases 487,450 Shares of Akero Therapeutics, Inc. (NASDAQ:AKRO) - MarketBeat
Redmile Group LLC Sells 226,994 Shares of Akero Therapeutics, Inc. (NASDAQ:AKRO) - MarketBeat
Point72 Asset Management L.P. Acquires Shares of 1,303,323 Akero Therapeutics, Inc. (NASDAQ:AKRO) - MarketBeat
Akero therapeutics COO Jonathan Young sells $321,310 in stock By Investing.com - Investing.com Canada
Akero Therapeutics CEO Andrew Cheng sells $802,250 in shares By Investing.com - Investing.com Nigeria
Akero Therapeutics CEO Andrew Cheng sells $802,250 in shares - Investing.com India
Akero therapeutics COO Jonathan Young sells $321,310 in stock - Investing.com
Why Is Akero Therapeutics, Inc. (AKRO) Among the Best Small-Cap Biotech Stocks With Massive Potential According to Hedge Funds? - Insider Monkey
Janus Henderson Group PLC Buys 201,225 Shares of Akero Therapeutics, Inc. (NASDAQ:AKRO) - MarketBeat
Cinctive Capital Management LP Buys Shares of 65,307 Akero Therapeutics, Inc. (NASDAQ:AKRO) - MarketBeat
Erste Asset Management GmbH Purchases New Position in Akero Therapeutics, Inc. (NASDAQ:AKRO) - MarketBeat
Liver Cirrhosis Market Key Trends, Leading Players, and Future - openPR
Intech Investment Management LLC Takes Position in Akero Therapeutics, Inc. (NASDAQ:AKRO) - MarketBeat
Akero Therapeutics, Inc. (NASDAQ:AKRO) Shares Acquired by Fred Alger Management LLC - MarketBeat
Akero Therapeutics, Inc. (NASDAQ:AKRO) Receives Average Rating of "Moderate Buy" from Brokerages - MarketBeat
Connor Clark & Lunn Investment Management Ltd. Reduces Position in Akero Therapeutics, Inc. (NASDAQ:AKRO) - Defense World
Connor Clark & Lunn Investment Management Ltd. Trims Holdings in Akero Therapeutics, Inc. (NASDAQ:AKRO) - MarketBeat
Akero Therapeutics, Inc. (NASDAQ:AKRO) Stake Boosted by Propel Bio Management LLC - MarketBeat
Akero Therapeutics to Present at the 7th Annual Evercore ISI HealthCONx Conference - The Manila Times
Non-alcoholic Steatohepatitis (NASH) Treatment Market 2032: Clinical Trials, Medication, EMA, PDMA, FDA Approvals, Epidemiology, Therapies, Companies by DelveInsight - The Globe and Mail
How To Trade (AKRO) - Stock Traders Daily
NASH Updates: Boston Pharma, Viking Line Up As Serious Competitors - Citeline News & Insights
Akero Therapeutics' chief development officer sells $251,274 in stock - Investing.com India
Citigroup Initiates Coverage of Akero Therapeutics (AKRO) with Buy Recommendation - MSN
Akero Therapeutics Inc (AKRO) 財務データ
収益
当期純利益
現金流量
EPS
Akero Therapeutics Inc (AKRO) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| Yale Catriona | Chief Development Officer |
Dec 16 '24 |
Option Exercise |
21.10 |
9,074 |
191,461 |
104,722 |
| Yale Catriona | Chief Development Officer |
Dec 16 '24 |
Sale |
29.11 |
9,074 |
264,117 |
95,648 |
| Rolph Timothy | Chief Scientific Officer |
Dec 17 '24 |
Option Exercise |
19.87 |
3,800 |
75,506 |
182,137 |
| Rolph Timothy | Chief Scientific Officer |
Dec 17 '24 |
Sale |
31.10 |
3,800 |
118,172 |
178,337 |
2.88%
2.65%
大文字化:
|
ボリューム (24 時間):